Quarterly ResultMay 12, 2026, 04:42 PM
Inhibikase Therapeutics Q1 Net Loss $(16.38)M; Cash & Securities $170.4M
AI Summary
Inhibikase Therapeutics reported a net loss of $(16.38) million for Q1 2026, an increase from $(13.68) million in Q1 2025. Despite increased operating expenses, the company maintained a strong liquidity position with $170.4 million in cash, cash equivalents, and marketable securities as of March 31, 2026, which is projected to fund operations for at least the next twelve months. The company is currently enrolling patients in its Phase 3 clinical study for IKT-001 for Pulmonary Arterial Hypertension.
Key Highlights
- Net loss for Q1 2026 was $(16,380,840), compared to $(13,678,735) in Q1 2025.
- Net loss per share was $(0.10) for Q1 2026, an improvement from $(0.15) in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $170.4 million as of March 31, 2026.
- Net cash used in operating activities increased to $(12,059,722) in Q1 2026 from $(4,103,530) in Q1 2025.
- Research and development expenses rose to $10,839,150 in Q1 2026 from $10,513,579 in Q1 2025.
- Selling, general and administrative expenses increased to $7,376,123 in Q1 2026 from $5,249,291 in Q1 2025.
- The company secured $2,897,611 in net proceeds from common stock, pre-funded warrants, and warrants issuance.
- Contingent consideration liability decreased from $3,061,501 at Dec 31, 2025 to $0 at Mar 31, 2026.
Price Impact
More from IKT